EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSCJAG00000015653
Gene Symbol: DHCR24
5 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSCJAG00000016954
Gene Symbol: HMGCR
5 Cross references
272 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSCJAG00000014801
Gene Symbol: PDPK1
5 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSCJAG00000016882
Gene Symbol: HPD
5 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S13-Like

Ensembl ID : ENSCJAG00000009564
Gene Symbol: LOC100393007
4 Cross references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S15a-Like

Ensembl ID : ENSCJAG00000074719
Gene Symbol: LOC118150206
4 Cross references
117 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S15a-Like

Ensembl ID : ENSCJAG00000084694
Gene Symbol: LOC108589884
4 Cross references
117 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S24-Like

Ensembl ID : ENSCJAG00000077358
Gene Symbol: LOC100385442
4 Cross references
146 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S27-Like

Ensembl ID : ENSCJAG00000076088
Gene Symbol: LOC108594116
4 Cross references
78 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S27-Like

Ensembl ID : ENSCJAG00000082512
Gene Symbol: LOC108593120
4 Cross references
80 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S27-Like

Ensembl ID : ENSCJAG00000070697
Gene Symbol: LOC108588476
4 Cross references
78 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S29-Like

Ensembl ID : ENSCJAG00000071958
Gene Symbol: LOC108587804
4 Cross references
122 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).